Lynx Investment Advisory Gilead Sciences, Inc. Transaction History
Lynx Investment Advisory
- $139 Billion
- Q3 2024
A detailed history of Lynx Investment Advisory transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Lynx Investment Advisory holds 8,205 shares of GILD stock, worth $740,008. This represents 0.5% of its overall portfolio holdings.
Number of Shares
8,205
Previous 8,221
0.19%
Holding current value
$740,008
Previous $564 Million
21.96%
% of portfolio
0.5%
Previous 0.42%
Shares
2 transactions
Others Institutions Holding GILD
# of Institutions
1,923Shares Held
994MCall Options Held
10.5MPut Options Held
9.75M-
Black Rock Inc. New York, NY121MShares$10.9 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA115MShares$10.4 Billion0.18% of portfolio
-
Capital World Investors Los Angeles, CA76.5MShares$6.9 Billion1.03% of portfolio
-
Capital Research Global Investors Los Angeles, CA61.8MShares$5.57 Billion1.12% of portfolio
-
State Street Corp Boston, MA60.2MShares$5.43 Billion0.21% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $113B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...